HC Wainwright & Co. Assumes Moleculin Biotech at Buy, Announces Price Target of $4

Benzinga · 06/09 11:32
HC Wainwright & Co. analyst Joseph Pantginis assumes Moleculin Biotech (NASDAQ:MBRX) with a Buy rating and announces Price Target of $4.